Abstract | OBJECTIVE: METHOD: This double-blind multisite trial randomly assigned pediatric patients with early-onset schizophrenia and schizoaffective disorder to treatment with either olanzapine (2.5-20 mg/day), risperidone (0.5-6 mg/day), or molindone (10-140 mg/day, plus 1 mg/day of benztropine) for 8 weeks. The primary outcome was response to treatment, defined as a Clinical Global Impression (CGI) improvement score of 1 or 2 and >or=20% reduction in Positive and Negative Syndrome Scale (PANSS) total score after 8 weeks of treatment. RESULTS: CONCLUSIONS:
|
Authors | Linmarie Sikich, Jean A Frazier, Jon McClellan, Robert L Findling, Benedetto Vitiello, Louise Ritz, Denisse Ambler, Madeline Puglia, Ann E Maloney, Emily Michael, Sandra De Jong, Karen Slifka, Nancy Noyes, Stefanie Hlastala, Leslie Pierson, Nora K McNamara, Denise Delporto-Bedoya, Robert Anderson, Robert M Hamer, Jeffrey A Lieberman |
Journal | The American journal of psychiatry
(Am J Psychiatry)
Vol. 165
Issue 11
Pg. 1420-31
(Nov 2008)
ISSN: 1535-7228 [Electronic] United States |
PMID | 18794207
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antipsychotic Agents
- Benzodiazepines
- Risperidone
- Olanzapine
- Molindone
|
Topics |
- Adolescent
- Antipsychotic Agents
(adverse effects, therapeutic use)
- Benzodiazepines
(adverse effects, therapeutic use)
- Child
- Double-Blind Method
- Female
- Humans
- Male
- Molindone
(adverse effects, therapeutic use)
- Olanzapine
- Psychiatric Status Rating Scales
- Psychotic Disorders
(diagnosis, drug therapy, psychology)
- Risperidone
(adverse effects, therapeutic use)
- Schizophrenia
(diagnosis, drug therapy)
- Schizophrenic Psychology
|